Effects of Cerebrolysin on the Neurodevelopmental Outcomes in Infants with Down Syndrome: A Randomized Controlled Pilot Trial

El-Din, Ahmed Salah; Yahia, Sohier; Zeid, Mayada Sabry; El-Hadidy, Mohamed Adel; Wahba, Yahya

doi:10.1080/19315864.2022.2098433

Cited by 1 publication

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the neurotrophic pentameric mixture cerebrolysin®, currently approved in several countries for the treatment of dementia, was reported to improve neurodevelopment in infants with Down syndrome in a phase II trial. 21 Another recently published target is gonadotropin-releasing hormone, which presented an age-related deficit in the Ts65Dn Down syndrome mouse model. Pulsatile gonadotropin-releasing hormone administration corrected synaptic plasticity and cognitive deficits in trisomic mice and showed positive results on a small group of seven male individuals with Down syndrome.…”

Section: W H At H a Ppe N E D I N Th E L Ast 10 Y E A R S?mentioning

confidence: 99%

“…New targets or other types of intervention are also being explored (Figure 2). For example, the neurotrophic pentameric mixture cerebrolysin®, currently approved in several countries for the treatment of dementia, was reported to improve neurodevelopment in infants with Down syndrome in a phase II trial 21 . Another recently published target is gonadotropin‐releasing hormone, which presented an age‐related deficit in the Ts65Dn Down syndrome mouse model.…”

Section: What Happened In the Last 10 Years?mentioning

confidence: 99%

See 1 more Smart Citation

State‐of‐the‐art therapy for Down syndrome

Lorenzón

Musoles-Lleó

Turrisi

et al. 2023

Develop Med Child Neuro

View full text Add to dashboard Cite

Down syndrome is the most common chromosomal disorder, caused by a third copy of all or part of chromosome 21 (HSA21), and the most complex and prevalent genetic cause of intellectual disability. 1 It is a chronic, multifactorial disorder that affects brain development and function, impairing cognition and adaptive behaviour. 2 Moreover, Down syndrome co-occurs with autism and epilepsy and is considered a genetic form of Alzheimer disease. 3 In addition, individuals with Down syndrome have a high prevalence of endocrine disorders and obesity, leading to type 2 diabetes, insulin resistance, and neuroinflammation, 4 which, in turn, contribute to cognitive deficits.In the last decade, an important effort was made to better understand the pathogenetic mechanisms involved in Down

show abstract

Section: W H At H a Ppe N E D I N Th E L Ast 10 Y E A R S?mentioning

confidence: 99%

Section: What Happened In the Last 10 Years?mentioning

confidence: 99%